Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.18
$3.17
$1.10
▼
$4.18
$819.45M1.0714.72 million shsN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.29
-0.4%		$295.88
$156.91
▼
$326.63
$5.71B1.13275,164 shs152,535 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%0.00%0.00%+1.60%+55.12%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-0.38%-2.82%-5.91%+24.84%+84.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.18
$3.17
$1.10
▼
$4.18
$819.45M1.0714.72 million shsN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.29
-0.4%		$295.88
$156.91
▼
$326.63
$5.71B1.13275,164 shs152,535 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%0.00%0.00%+1.60%+55.12%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-0.38%-2.82%-5.91%+24.84%+84.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.00
Hold$5.5474.21% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$335.7517.28% Upside

Current Analyst Ratings Breakdown

Latest LGND and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$330.00
8/11/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Buy (B-)
8/7/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$340.00 ➝ $345.00
8/6/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$289.00 ➝ $358.00
8/3/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$285.00 ➝ $326.00
7/21/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$387.00
7/15/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$262.00 ➝ $340.00
7/9/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$266.00 ➝ $388.00
7/8/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$255.00 ➝ $332.00
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$403.14M2.03N/AN/A($1.26) per share-2.52
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M21.29$7.85 per share36.46$48.53 per share5.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$22.68M-$0.06N/A14.45N/A0.12%-0.14%0.12%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$9.3530.6233.802.2967.88%20.06%11.68%11/5/2026 (Estimated)

Latest LGND and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.97$2.37+$0.40$2.22$61.30 million$63.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.53
1.18
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
1.16
31.18
30.96

Institutional Ownership

CompanyInstitutional Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.60%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200257.69 million253.57 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.94 million18.82 millionOptionable

Recent News About These Companies

Craig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)
August 20 at 8:02 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LGND/pressreleases/3736873/craig-hallum-keeps-their-buy-rating-on-ligand-pharma-lgnd/
Ligand Pharma (LGND) Gets a Buy from Oppenheimer
August 20 at 8:02 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LGND/pressreleases/3736212/ligand-pharma-lgnd-gets-a-buy-from-oppenheimer/
Ligand Pharmaceuticals Earnings Call Signals Royalty-Driven Surge
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ligand-pharmaceuticals-earnings-call-signals-royalty-driven-surge?utm_source=marketbeat.com&utm_medium=referral
Ligand Pharmaceuticals (NASDAQ:LGND) Research Coverage Started at Leerink Partners
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965411
Octavio Espinoza Sells 31,641 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30964338
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-08-16/
Jason Haas Sells 7,138 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-08-15/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-director-jason-haas-sells-7138-shares-2026-08-14/
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-ligand-pharmaceuticals-nasdaqlgnd-cfo-sells-31641-shares-of-stock-2026-08-14/
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-now-covered-by-leerink-partners-2026-08-14/
Breakout watch: Savvy investors bet millions on royalty-fueled pharma stock
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/breakout-watch-savvy-investors-bet-millions-on-royalty-fueled-pharma-stock/ar-AA2a1hZI
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AMN/pressreleases/3739538/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby/
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-incorporated-nasdaqlgnd-receives-average-recommendation-of-moderate-buy-from-analysts-2026-08-09/
Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-issues-quarterly-earnings-results-2026-08-08/
California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-acquires-4987-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-08-08/
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-stock-price-expected-to-rise-royal-bank-of-canada-analyst-says-2026-08-07/
Ligand Pharmaceuticals Q2 Earnings Call Highlights
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-q2-earnings-call-highlights-2026-08-06/
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932313-ligand-pharmaceuticals-incorporated-lgnd-q2-2026-earnings-call-transcript
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $358.00 Price Target at HC Wainwright
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-given-new-35800-price-target-at-hc-wainwright-2026-08-06/
Ligand Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932238-ligand-pharmaceuticals-incorporated-2026-q2-results-earnings-call-presentation
Ligand Reports Second Quarter 2026 Financial Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/ligand-reports-second-quarter-2026-financial-results-1036419026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$286.29 -1.10 (-0.38%)
As of 08/21/2026 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas